| 기면증의 약물 치료 |
|
한진규 |
|
고려대학교 안암병원 신경과 |
| |
| Pharmacotherapy for Narcolepsy |
| Jinkyu Han |
| Department of Neurology, Korea University Anam Hospital |
| Corresponding Author:
Jinkyu Han ,Tel: +82-2-920-5837, Fax: +82-2-920-5742, Email: dystonia@hanmail.net |
|
Received: December 1, 2004 Accepted: December 20, 2004 Published online: December 31, 2004 |
|
|
Share : 
|
|
| ABSTRACT |
|
Excessive daytime sleepiness(EDS) has recognized consequences such as road traffic accidents, impaired psychological functioning and
reduced work performance. EDS can result from multiple causes such as sleep deprivation, sleep fragmentation, neurological, psychiatric and
circadian rhythm disorders. Treating the underlying causes of EDS remains the mainstay of therapy but in those who continue to be
excessively sleepy, further treatment may be warranted. Traditionally, the amphetamine derivatives, methylphenidate and pemoline(collectively
sympathomimetic) psychostimulants were the commonest form of therapy for EDS, particularly in conditions such as narcolepsy. More
recently, the advent of modafinil has broadened the range of therapeutic options. Modafinil has a safer side effect profile and as a result,
interest in this drug for the management of EDS in other disorders, as well as narcolepsy, has increased considerably. There is a growing
school of thought that modafinil may have a role to play in other indications such as obstructive sleep apnea/hypopnea syndrome already
treated by nasal continuous positive airway pressure but persisting EDS, shift work sleep disorders, neurological causes of sleepiness, and
healthy adults performing sustained operations, particularly those in the military. However, until adequately powered randomized-controlled
trials confirm long-term efficacy and safety, the recommendation of wakefulness promoters in healthy adults cannot be justified. |
| Keywords:
Excessive daytime sleepiness | Psychostimulants | Antidepressant |
|
|
|
PDF Links
Full text via DOI
Download Citation 
